Sumi Sukanaya News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Covaxin offers 93.4 per cent protection from severe Covid, 65.2 per cent immunity against Delta variant There had been massive pressure on Bharat Biotech, which has developed the vaccine with support from the ICMR, to release full data of the efficacy trials carried out earlier this year. Share Via Email   |  A+A A- A health worker administers the Covaxin COVID-19 vaccine during a special vaccination drive in Hyderabad. (Photo | AP) NEW DELHI: Covaxin has shown an overall efficacy of 77.8 % against symptomatic Covid-19, 93.4 % efficacy against severe disease and 65.2 % efficacy against delta variant of SARS CoV 2, the results of its phase 3 clinical trials conducted on nearly 26,000 individuals have shown.  

Sumi sukanaya duttaRajeev jayadevanIndian medical associationSumi sukanayaBharat biotechIndian medicalஇந்தியன் மருத்துவ சங்கம்பாரத் பயோடெக்இந்தியன் மருத்துவ